Shares of Dynavax Technologies Corp. reversed premarket losses to trade flat at the open Monday, after the biotech reported findings from an early-stage trial of its SD-101 treatment for metastatic melanoma in combination with Merck & Co.’s Keytruda. Dynavax said the trial produced results for efficacy in 17 patients and safety in 22 patients. “In patients naïve to anti-PD-1 treatment, responses were observed in six out of seven patients, for an Overall Response Rate (ORR) of 86%,” the company said in a statement. “This includes two (29%) complete responses (CR) and four (57%) partial responses (PR). Target tumor shrinkage was observed in all 7 evaluable patients.” Dynavax Chief Medical Officer Robert Janssen said the results allow the company explore higher doses of the drug. Shares have fallen 63% in the last 12 months, while the S&P 500 has gained 19%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News